(2R,3S)-N-[2-(dimethylamino)ethyl]-3-(2,2-dimethylpropanoyl)-N-methylbicyclo[2.2.1]heptane-2-carboxamide

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (2R,3S)-N-[2-(dimethylamino)ethyl]-3-(2,2-dimethylpropanoyl)-N-methylbicyclo[2.2.1]heptane-2-carboxamide
• 化学式: C₁₈H₃₂N₂O₂
• 分子量: 308.5
• InChiKey: FONNUDCBVBMNRD-PFSRBDOWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  40.6
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• PRODRUG COMPRISING A DRUG LINKER CONJUGATE
  申请人：ASCENDIS PHARMA A/S

  公开号：US20150057221A1

  公开（公告）日：2015-02-26

  The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising a drug linker conjugate D-L, wherein -D is an amine containing biologically active moiety; and -L is a non-biologically active linker moiety -L 1 represented by formula (I): wherein the dashed line indicates the attachment to the amine of the biologically active moiety and wherein R 1 , R 1a , R 2 , R 2a , R 3 , R 3a , X, X 1 , X 2 , X 3 have the meaning as indicated in the description and the claims and wherein L 1 is substituted with one to four groups L 2 -Z and optionally further substituted, provided that the hydrogen marked with the asterisk in formula (I) is not replaced by a substituent; wherein L 2 is a single chemical bond or a spacer; and Z is a carrier group. The invention also relates to A-L, wherein A is a leaving group, pharmaceutical composition comprising said prodrugs and their use as medicaments.

  本发明涉及一种前药或其药学上可接受的盐，包括药物连接物D-L，其中-D是含有生物活性基团的胺基；而-L是非生物活性连接基团-L1，其由式（I）表示：其中虚线表示连接到生物活性基团的胺基，其中R1、R1a、R2、R2a、R3、R3a、X、X1、X2、X3具有说明书和权利要求中所示的含义，而L1被一到四个L2-Z基团取代，并且可以选择进一步取代，但是在式（I）中标记为星号的氢原子不被取代；其中L2是单一化学键或间隔物；Z是载体基团。本发明还涉及A-L，其中A是离去基团，包括所述前药的制药组合物及其作为药物的用途。
• Polymeric Hyperbranched Carrier-Linked Prodrugs
  申请人：Hersel Ulrich

  公开号：US20140243254A1

  公开（公告）日：2014-08-28

  The present invention relates to water-soluble carrier-linked prodrugs of formula (I), wherein POL is a polymeric moiety, each Hyp is independently a hyperbranched moiety, each moiety SP is independently a spacer moiety, each L is independently a reversible prodrug linker moiety, m is 0 or 1, each n is independently an integer from 2 to 200 and each x is independently 0 or 1. It further relates to pharmaceutical compositions comprising said water-soluble carrier-linked prodrugs and methods of treatment.